Global Orally Disintegrating Tablet Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Proton Pump Inhibitors, Anti-Psychotics, Anti-Hypertensives, Anti-Epileptics, and Others), By Indication (GI Diseases, CNS Diseases, CVS Disorders, and Others), By Distribution Channel (Drug Stores, Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Orally Disintegrating Tablet Market Insights Forecasts to 2033

• The Global Orally Disintegrating Tablet Market Size was estimated at USD 13.05 billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 8.11% from 2023 to 2033
• The Worldwide Orally Disintegrating Tablet Market Size is expected to Reach USD 28.45 billion by 2033
• Asia Pacific is predicted to grow at the fastest CAGR throughout the projection period

The Global Orally Disintegrating Tablet Market Size is predicted to exceed USD 28.45 billion by 2033, growing at a CAGR of 8.11% from 2023 to 2033.

Market Overview

The orally disintegrating tablet market is categorized under the pharmaceutical industry. It involves the production and distribution of disintegrant tablets that rapidly dissolve in the mouth without the need for an additional liquid and are used in the management of numerous diseases. Orally disintegrating tablets are solid dosage forms designed to enhance the disintegration and dissolution rates of a pharmaceutical product. Such types of tablets are mostly recommended for patients with dysphagia. Orally disintegrating tablets are also preferred as fast-dissolving tablets, rapimelts, porous tablets, orodispersible tablets, quick-disintegrating tablets, fast-disintegrating tablets, rapid-dissolving tablets, and mouth-dissolving tablets. There are several methods available for the formulation of oral disintegrating tablets such as spray drying, mold sublimation, direct compression, freeze-drying, and spray-drying. Among these, the direct compression method is widely used owing to its cost-effectiveness, ease of use, and results in low-friability tablets. The marketed formulation of the orally disintegrating tablets is Lansonor-Kid, Ondagen-MD, Geometil -MD., etc.

The rising occurrence of deglutition disorders such as dysphagia, achalasia, etc in patients suffering from chronic diseases such as hypertension, cancer, etc., escalates the need for oral disintegrating tablets for rapid disintegration and management of the disease and extensive usage of the oral disintegrating tablets results in an expansion of the market. For instance, the data provided by the National Library of Medicine, claims that dysphagia, a subjective swallowing sensation, negatively impacts the quality of life, and work productivity, and is the 10th leading cause of ambulatory care visits in the US. The prevalence of dysphagia among populations ranges from 2% to 20% worldwide.

The increasing prevalence of hypertension in the elderly population accelerates the need for oral disintegrating tablets as elderly individuals face swallowing difficulties due to a history of chronic diseases and weakened pharyngeal muscles. For example, the data published in the Journal, Clinical Cardiology states that hypertension, a growing global health concern, is projected to affect one-third of the global population by 2025 owing to the aging population and rising obesity rates. Around 60 years of age, 60% of the US population has high hypertension (HTN) with 65% of men and 75% of women developing high blood pressure by 70 years. By 2060, 25% of the US population will be 65 years or older, with nearly 20 million surpassing the eighth decade of life. The prevalence of HTN will rise as up to 50% of US people live to be 100 years old.

Report Coverage

This research report categorizes the global orally disintegrating tablet market based on various segments and regions, forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global orally disintegrating tablet market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global orally disintegrating tablet market.

Driving Factors:

The orally disintegrating tablet (ODT) market is driven by its convenience in medication delivery, particularly for pediatric and geriatric patients. ODTs disintegrate rapidly in the mouth, eliminating the need for water or swallowing difficulties, making them ideal for conditions like migraines or allergies. The demand for fast-acting drugs has surged, making ODTs ideal for quick onset of therapeutic effects. The trend toward personalized medicine is accelerating the ODT market, with companies investing in research to create customized tablets. ODTs have rapid absorption, a quick recovery process, and no need for swallowing, making them suitable for busy lifestyles. Patients with gastrointestinal issues prefer ODTs due to their ease of intake. Suppliers focus on aftertaste and mouthfeel to enhance the appeal of ODTs. ODTs offer ease and accuracy, promoting better patient adherence to treatment regimens. They have a longer shelf life due to improved stability and manufacturing processes.

Restraining Factors

High-cost of formulation methods of orally disintegrating tablets, limited drug load capacity, and complications in maintaining stability, may impede the growth of the market. ODTs face complex regulatory approvals due to specialized manufacturing processes and quality control, impacting market growth and restraining manufacturers' ability to navigate the regulatory landscape.

Market Segmentation

The global orally disintegrating tablet market share is classified into drug type, indication, and distribution channel.

• The anti-psychotics segment dominated the market with 38.92% of the share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the drug type, the global orally disintegrating tablet market is categorized into proton pump inhibitors, anti-psychotics, anti-hypertensives, anti-epileptics, and others. Among these, the anti-psychotics segment dominated the market with 38.92% of the share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segment growth is attributed to the rising trend of innovative drug delivery systems, greater efficacy and safety profile, effective medications for the treatment of schizophrenia and bipolar disorders, increasing proportion of research and development, and ease of administration than the standard drugs.

• The CNS diseases segment accounted for the largest market share of 40.23% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indication, the global orally disintegrating tablet market is categorized into GI diseases, CNS diseases, CVS disorders, and others. Among these, the CNS diseases segment accounted for the largest market share of 40.23% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is attributed to the rising prevalence of central nervous system diseases such as Parkinson’s disease, Alzheimer's disease, and mental disorders, enhanced patient compliance with using ODT formulation for the management of CNS diseases, minimizes the first pass metabolism effect, and improved therapeutic efficacy.

• The hospital pharmacies segment held the largest market share of 28.20% in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global orally disintegrating tablet market is categorized into drug stores, hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment held the largest market share of 28.20% in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe. This segment growth is facilitated by the collaborations of the hospital pharmacies and hospitals to give better patient health outcomes, provision of compounding and dispensing of medications, regulatory compliance, access to patient records for better patient outcomes, cost-effective drug acquisition, and facilities of vital consultation services.

Regional Segment Analysis of the Global Orally Disintegrating Tablet Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global orally disintegrating tablet market over the predicted timeframe.

North America is anticipated to hold the largest share of the global orally disintegrating tablet market over the predicted timeframe. In North America, the consumption of oral disintegrating tablets (ODTs) has increased as chronic diseases like diabetes, heart disease, and abnormalities in the central nervous system grow prevalent. Travelers are likely to find these pills helpful since they dissolve fast in the mouth without the need for water. Pharmaceutical firms are spending money on advertising and marketing initiatives to inform patients and medical professionals about the benefits of ODTs. These businesses have been encouraged to invest in this market area by regulatory agencies such as the FDA. Diseases of the cardiovascular and central nervous systems are becoming more common, which has prompted the creation of simple-to-use medications. Growing regulatory approvals for ODTs, which provide quicker therapeutic benefits for a range of illnesses, support the expansion of the industry in this sector.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The cost-effectiveness of oral disintegrating tablets in comparison to other dosage forms is one of the factors contributing to this growth. Orally disintegrating pills have additionally grown more prevalent in these areas as a result of patients and healthcare professionals' increasing awareness of their beneficial effects and adaptability. The rising prevalence of chronic diseases owing to sedentary lifestyles and secondary factors propels the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global orally disintegrating tablet market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Bausch Health
• Sun Pharmaceutical Industries Ltd.
• Merck and Co., Inc.
• Bayer AG
• GlaxoSmithKline plc.
• Mylan N.V.
• Johnson & Johnson Services, Inc.
• Eli Lily Company
• Pfizer Inc.
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2025, Sunshine Biopharma, a Canadian pharmaceutical company, launched two new generic prescription drugs, Olanzapine and Olanzapine ODT. Olanzapine, a generic version of Zyprexa, is used for the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as the acute treatment of manic or mixed episodes of bipolar-I disorder.

• In July 2024, Mind Medicine, a biopharmaceutical company, received a US patent for its proprietary and pharmaceutically optimized form of lysergide (LSD), MM120. MM120 is currently in clinical development for adults with generalized anxiety disorder (GAD) and has the potential to treat other brain health disorders. The patent covers the pharmaceutical formulation, manufacturing methods, and treatment methods for MM120 ODT, which is the first US patent issued on the MM120 ODT formulation. The patent extends MindMed's intellectual property protection for MM120 until 2041.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global orally disintegrating tablet market based on the below-mentioned segments:

Global Orally Disintegrating Tablet Market, By Drug Type

• Proton Pump Inhibitors
• Anti-Psychotics
• Anti-Hypertensives
• Anti-Epileptics
• Others

Global Orally Disintegrating Tablet Market, By Indication

• GI Diseases
• CNS Diseases
• CVS Disorders
• Others

Global Orally Disintegrating Tablet Market, By Distribution Channel

• Drug Stores
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Orally Disintegrating Tablet Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa